GSK (NYSE:GSK) Releases FY 2025 Earnings Guidance

GSK (NYSE:GSK) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 2.090-2.130 for the period, compared to the consensus EPS estimate of 4.520. The company issued revenue guidance of $40.1 billion-$40.9 billion, compared to the consensus revenue estimate of $34.3 billion.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. StockNews.com lowered GSK from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 21st. Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Guggenheim lowered GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Finally, Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and dropped their price target for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. Six equities research analysts have rated the stock with a hold rating, one has given a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Price Performance

Shares of GSK stock opened at $34.84 on Wednesday. The stock has a market cap of $72.22 billion, a price-to-earnings ratio of 22.63, a PEG ratio of 1.38 and a beta of 0.64. The business’s fifty day moving average is $34.10 and its 200 day moving average is $37.60. GSK has a twelve month low of $31.72 and a twelve month high of $45.92. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98.

GSK (NYSE:GSK) last announced its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 50.62% and a net margin of 7.97%. Research analysts expect that GSK will post 3.92 EPS for the current fiscal year.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.